Free Trial

Cara Therapeutics (CARA) Insider Trading & Ownership

Cara Therapeutics logo
$0.42 +0.01 (+3.35%)
(As of 12/20/2024 05:51 PM ET)

Cara Therapeutics (NASDAQ:CARA) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
3.10%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
4
Amount Of
Insider Selling
(Last 12 Months)
$33,858.03
Get CARA Insider Trade Alerts

Want to know when executives and insiders are buying or selling Cara Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

CARA Insider Buying and Selling by Quarter

Cara Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/2/2024Christopher PosnerCEOSell3,936$0.75$2,952.00  
4/5/2024Joana GoncalvesInsiderSell2,753$0.83$2,284.99  
2/8/2024Christopher PosnerCEOSell35,575$0.53$18,854.75  
2/8/2024Ryan D MaynardCFOSell5,488$0.53$2,908.64  
2/8/2024Scott TerrillionInsiderSell7,770$0.53$4,118.10  
2/1/2024Christopher PosnerCEOSell4,981$0.55$2,739.55  
(Data available from 1/1/2013 forward)

CARA Insider Trading Activity - Frequently Asked Questions

The list of insiders at Cara Therapeutics includes Christopher Posner, Frederique Ph.D. Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Ryan D Maynard, Scott Terrillion, and Thomas Charles Reilly. Learn more on insiders at CARA.

3.10% of Cara Therapeutics stock is owned by insiders. Learn more on CARA's insider holdings.

The following insiders have sold CARA shares in the last 24 months: Christopher Posner ($108,877.31), Frederique Ph.D. Menzaghi ($63,437.08), Joana Goncalves ($60,489.48), Ryan D Maynard ($2,908.64), and Scott Terrillion ($25,015.14).

Insiders have sold a total of 96,119 Cara Therapeutics shares in the last 24 months for a total of $260,727.65 sold.

Cara Therapeutics Key Executives



This page (NASDAQ:CARA) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners